The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy

Journal of Research in Medical Sciences

Volumn 19, Issue 2, 2014, Pages 106-111

  Ghasemi, Majid ^a   Ansari, Maryam ^a   Basiri, Keivan ^a   Shaigannejad, Vahid ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Botulinum toxin type A; Diabetic peripheral neuropathy; Pain

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; COLD SENSATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTRIC SHOCK; ELECTRODIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; HYPESTHESIA; INSULIN TREATMENT; MALE; MIDDLE AGED; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; PAIN ASSESSMENT; PARESTHESIA; POLYNEUROPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SKIN TINGLING; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

EID: 84896453418     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tesfaye S. Recent advances in the management of diabetic symmetrical polyneuropathy. J Diabetes Investig 2010;2:33-42.
2. Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, Johnsen B, de Carvalho M, Fawcett PR, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clin Neurophysiol 2005;116:1571-80.
3. Baron R. Mechanisms of disease: Neuropathic pain - A clinical perspective. Nat Clin Pract Neurol 2006;2:95-106.
4. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-22.
5. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 2004;351:48-55.
6. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005;118:289-305.
7. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237-51.
8. Ziegler D. Painful diabetic neuropathy: Treatment and future aspects. Diabetes Metab Res Rev 2008;24 Suppl 1:S52-7.
9. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in openlabel, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25:1663-76.
10. Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70:2305-13.
11. Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep 2010;2:52.
12. Sim WS. Application of botulinum toxin in pain management. Korean J Pain 2011;24:1-6.
13. Najafi MR, Rashidi I. Antispasmodic effect of botulinum toxin type A on spastic hemiplegia due to cerebrovascular accident. Arch Iran Med 2003;6:265-8.
14. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274-83.
15. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology 2009;72:1473-8.
16. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002;18:S177-81.
17. Restivo DA, Marchese-Ragona R, Lauria G, Squatrito S, Gullo D, Vigneri R. Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy. Diabetes Care 2006;29:2650-3.
18. Hummel M, Geigenberger G, Brand J, Ziegler AG, Füchtenbusch M. New therapeutic approaches to diabetic gastroparesis. Med Klin (Munich) 2008;103:514-8.
19. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.
20. Jensen MP, Friedman M, Bonzo D, Richards P. The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain 2006;22:97-103.
21. Ranoux D. Botulinum toxin and painful peripheral neuropathies: What should be expected? Rev Neurol (Paris) 2011;167:46-50.
22. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93.
23. Simpson LL. Identifi cation of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-93.
24. Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: Insights from animal models. Toxins (Basel) 2010;2:2890-913.
25. Bach-Rojecky L, Salković-Petrisić M, Lacković Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. Eur J Pharmacol 2010;633:10-4.